Drug Action
Mogamulizumab is a monoclonal antibody, which binds to the CCR4 receptor, thereby potentiating an immune response to cancer cells.
PDF page 943
Loading InternPractice…
Drug reference
Mogamulizumab is a monoclonal antibody, which binds to the CCR4 receptor, thereby potentiating an immune response to cancer cells.
PDF page 943
Mycosis fungoides (initiated by a specialist) | Sézary syndrome (initiated by a specialist) ▶BY INTRAVENOUS INFUSION ▶Adult: 1 mg/kg every week on days 1, 8, 15 and 22 of the first 28-day cycle, followed by 1 mg/kg every 2 weeks on days 1 and 15 of subsequent 28-day cycles, dose to be administered within 2 days of the scheduled day, for treatment interruption or discontinuation due to side-effects and infusion-related reactions—consult product literature
PDF page 943
Patients may need pre-medication to minimise infusion-related reactions. risk factors for cardiac disorders. risk of serious infection and/or viral reactivation such as hepatitis B. risk of transplant-related complications CAUTIONS, FURTHER INFORMATION ▶Pre-medication Manufacturer advises pre-medication with an antihistamine and an anti-pyretic—consult product literature. ▶Hepatitis B infection Manufacturer advises patients should be tested for hepatitis B infection before treatment initiation; expert advice on measures against hepatitis B reactivation should be sought for patients with positive hepatitis B serology. ▶Transplant-related complications Manufacturer advises patients who receive an allogeneic haematopoietic stem cell transplant within 50 days of mogamulizumab treatment are at higher risk of complications, such as Immune system and malignant disease severe graft-versus-host disease, and should be closely monitored.
PDF pages 943, 944
→Appendix 1: monoclonal antibodies
PDF page 944
▶Common or very common Anaemia. constipation. diarrhoea. fatigue. fever. headache. hypothyroidism. increased risk of infection. infusion related reaction. leucopenia. nausea. neutropenia. peripheral oedema. sepsis. skin reactions. stomatitis. thrombocytopenia. vomiting ▶Uncommon Hepatic disorders. tumour lysis syndrome ▶Frequency not known Cardiomyopathy. myocardial infarction. polymyositis. severe cutaneous adverse reactions (SCARs). viral infection reactivation
PDF page 944
Manufacturer advises effective contraception in male and female patients of childbearing potential during treatment and for at least 6 months after last treatment. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 944
Manufacturer advises avoid—limited information available. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 944
Manufacturer advises avoid during first few days after birth—possible risk from transfer of antibodies to infant. After this time, use during breast- feeding only if clinically needed.
PDF page 944
Manufacturer advises monitor electrolytes, hydration status and renal function, particularly in the first month of treatment—risk of tumour lysis syndrome.
PDF page 944
Manufacturer advises for intravenous infusion (Poteligeo ®), dilute to a concentration between 0.1 mg/mL to 3 mg/mL with Sodium Chloride 0.9%; give over at least 60 minutes through a low-protein binding 0.22 micron in-line filter. Resuscitation facilities should be available. l HANDLING AND STORAGE Store in a refrigerator (2–8°C) and protect from light—consult product literature for storage conditions after preparation of the infusion.
PDF page 944
There can be variation in the licensing of different medicines containing the same drug. Solution for infusion EXCIPIENTS: May contain Polysorbates A ▶Poteligeo (Kyowa Kirin Ltd) Mogamulizumab 4 mg per 1 ml Poteligeo 20mg/5ml concentrate for solution for infusion vials | 1 vial P £1,329.00 (Hospital only)
PDF page 944
Driving and skilled tasks Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of fatigue.
PDF page 944
1 mg/kg every week on days 1, 8, 15 and 22 of
First-line fragment. Read the complete Indications and Dose section above.
PDF page 943